Yuju Luo1, Yu Jiang2. 1. Department of Ultrasound, Daqing Oilfield General Hospital, Daqing, Heilongjiang Province, 163001, China. 2. Department of Bone Surgery, Daqing Oilfield General Hospital, Daqing, Heilongjiang Province, 163001, China.
Abstract
OBJECTIVE: To compare efficiency of trans-arterial chemo-embolization (TACE) plus high intensity focused ultrasound (HIFU), and TACE alone on patients with primary liver cancer. STUDY DESIGN: A descriptive, analytical study. PLACE AND DURATION OF STUDY: Department of Ultrasound, Daqing Oilfield General Hospital, China, from March 2015 to March 2017. METHODOLOGY: A total of 90 primary liver cancer patients were randomly divided into control group and observation group, 45 cases in each group. Control group was treated with TACE alone, while observation group was treated with HIFU plus TACE. Alpha-fetoprotein (AFP), alanine amino-transferase (ALT), aspartate amino-transferase (AST), total bilirubin (TBIL), and frequency of complications, were compared in the two groups. RESULTS: The total remission rate of observation group was higher than that of control group (p=0.017). At 6 months after treatment, AFP level in observation group was lower than that in control group (p <0.001). There was no statistical difference in liver function indicators of ALT, AST, and TBIL between two groups (p=0.968, 0.944 and 0.973, respectively). The incidence of digestive tract hemorrhage was lower than that in control group (p=0.049). After one year of follow-up, the tumor recurrence rate and tumor metastasis rate in observation group were lower than that of control group (p=0.036 and 0.044, respectively). CONCLUSION: Treatment of primary liver cancer by TACE plus HIFU has a higher overall remission rate, causes little damage to normal liver tissue, can fully kill tumor cells and reduce postoperative local recurrence and metastasis rate with less adverse reactions.
RCT Entities:
OBJECTIVE: To compare efficiency of trans-arterial chemo-embolization (TACE) plus high intensity focused ultrasound (HIFU), and TACE alone on patients with primary liver cancer. STUDY DESIGN: A descriptive, analytical study. PLACE AND DURATION OF STUDY: Department of Ultrasound, Daqing Oilfield General Hospital, China, from March 2015 to March 2017. METHODOLOGY: A total of 90 primary liver cancerpatients were randomly divided into control group and observation group, 45 cases in each group. Control group was treated with TACE alone, while observation group was treated with HIFU plus TACE. Alpha-fetoprotein (AFP), alanine amino-transferase (ALT), aspartate amino-transferase (AST), total bilirubin (TBIL), and frequency of complications, were compared in the two groups. RESULTS: The total remission rate of observation group was higher than that of control group (p=0.017). At 6 months after treatment, AFP level in observation group was lower than that in control group (p <0.001). There was no statistical difference in liver function indicators of ALT, AST, and TBIL between two groups (p=0.968, 0.944 and 0.973, respectively). The incidence of digestive tract hemorrhage was lower than that in control group (p=0.049). After one year of follow-up, the tumor recurrence rate and tumor metastasis rate in observation group were lower than that of control group (p=0.036 and 0.044, respectively). CONCLUSION: Treatment of primary liver cancer by TACE plus HIFU has a higher overall remission rate, causes little damage to normal liver tissue, can fully kill tumor cells and reduce postoperative local recurrence and metastasis rate with less adverse reactions.
Authors: Yun-Bing Wang; Rong Ma; Zhi-Biao Wang; Qiu-Ling Shi; Lian Zhang; Wen-Zhi Chen; Jian-Ping Gong; Jin Bai Journal: Front Oncol Date: 2022-03-28 Impact factor: 6.244